Comparative Pharmacology
Head-to-head clinical analysis: FYCOMPA versus LAMICTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYCOMPA versus LAMICTAL.
FYCOMPA vs LAMICTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-competitive AMPA receptor antagonist; inhibits glutamate-mediated excitatory neurotransmission by selectively targeting AMPA receptors.
Lamotrigine is a triazine antiepileptic drug that inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating presynaptic transmitter release of excitatory amino acids like glutamate and aspartate.
Initial: 2 mg orally once daily; titrate weekly by 2 mg increments to maintenance dose of 4-12 mg once daily depending on seizure type and tolerability; maximum 12 mg once daily.
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 150 mg twice daily or 200 mg twice daily (if taking valproate, reduced regimen).
None Documented
None Documented
Terminal elimination half-life is approximately 105 hours (range 80-120 hours) in patients with epilepsy; supports once-daily dosing.
14 hours (monotherapy); 7 hours (with enzyme-inducers); 30 hours (with valproate).
Renal: approximately 30% as unchanged drug; fecal: approximately 70% (mostly as metabolites, minimal unchanged).
Renal (70% as glucuronide metabolites, 2% as unchanged drug); fecal (2%); biliary (minor).
Category C
Category C
Anticonvulsant
Anticonvulsant